Articles by Arjun Menon
Telix Pharmaceuticals' TLX250-Px Shows Promise for Diagnosing Multiple Kidney Cancer Types Beyond Clear Cell RCC
New Phase 3 ZIRCON analysis reveals TLX250-Px (Zircaix®) potential for diagnosing various kidney cancers, expanding beyond clear cell renal cell carcinoma applications.
Novo Nordisk Launches Wegovy in China Before Eli Lilly, Capturing World's Largest Obesity Market
Novo Nordisk secures first-mover advantage launching Wegovy in China ahead of Eli Lilly's competing obesity drug, targeting massive untapped market opportunity.
ROIS Expands to US Market as Global CDMO with FDA Approval for Injectable Drug Manufacturing
ROIS establishes US operations as global CDMO with FDA, EMA, and other major regulatory approvals for end-to-end injectable drug manufacturing services.
Inflation Reduction Act Pharmaceutical Impact: What You Need to Know
Learn about the Inflation Reduction Act's effects on pharmaceutical pricing, focusing on key medications like insulin and cancer therapies for Medicare patients.
African Medicines Agency impact: Harmonizing Clinical Trials in Africa
The African Medicines Agency is transforming clinical trials in Africa, streamlining processes for drug approvals and improving access to essential medicines.
NMPA Conditional Approval: What You Need to Know About China's Expedited Drug Pathway
Learn about China's NMPA Conditional Approval process, designed to expedite access to critical medications like XYZ for cancer patients.
Kodiak Sciences KSI-101 Clinical Data to Be Presented at Scientific Conferences for Macular Edema Treatment
Kodiak Sciences will present KSI-101 clinical data for macular edema secondary to inflammation, with Phase 3 results expected in Q4 2026.
Plozasiran TGA Approval: REDEMPLO® Expands FCS Access in Australia
Arrowhead Pharmaceuticals has secured TGA approval for REDEMPLO® (plozasiran) in Australia, marking a significant step in providing a new treatment option for patients with Familial Chylomicronemia Syndrome (FCS). This approval broadens global access to plozasiran for this rare genetic disorder.
ANVISA Approves MagicTouch SCB: What You Need to Know
ANVISA has officially approved MagicTouch SCB, a groundbreaking treatment for chronic pain, offering new hope for patients seeking relief.
Soleno Therapeutics Faces Securities Fraud Lawsuit Over Alleged Sham Phase 3 Clinical Trials
Soleno Therapeutics hit with securities fraud allegations claiming company conducted fraudulent Phase 3 trials that led to FDA drug approval.
ANVISA Serialization Resolution: What You Need to Know About Brazil's Traceability Mandate
Discover the essentials of Brazil's ANVISA serialization resolution, a crucial mandate for drug traceability that impacts the pharmaceutical industry significantly.
TrialClinIQ Secures $150K Investment from Caduceus Capital to Transform Clinical Trial Recruitment with AI Technology
Houston-based TrialClinIQ raises $150K pre-seed funding and joins LAUNCH accelerator while opening $1.5M round to improve clinical trial access through AI.
Claruvis Pharmaceutical's Retoxin Becomes World's First Approved Recombinant Botulinum Toxin Type A in China
China's NMPA approves Retoxin, the world's first recombinant botulinum toxin type A, marking a technological breakthrough in aesthetic medicine treatments.
PSG 2026 Specialty Drug Benefits Report: Cost Management Remains Top Priority as Coverage Strategies Challenge Payers
PSG's 13th annual report reveals payers prioritize cost management while struggling with coverage strategies for new specialty drugs and indications.
![EMA Biosimilar Approvals 2024: Impact on [Specific Drug] Market & Pricing](/uploads/articles/ema-biosimilar-approvals-specific-drug-market-analysis-2024.webp)
EMA Biosimilar Approvals 2024: Impact on [Specific Drug] Market & Pricing
Discover how the 2024 EMA biosimilar approvals will affect the market dynamics and pricing strategies for [Specific Drug] used in treating [Indication].
PMC Organometallix Announces 10-25% Price Increases Across All Product Lines Effective May 2026
PMC Organometallix will implement 10-25% price increases on all products globally starting May 1, 2026, citing significant market condition changes.
Quasar Medical Opens New Thailand Manufacturing Facility to Expand MedTech Production Capacity
Quasar Medical inaugurates new Chonburi manufacturing facility in Thailand, boosting global production capacity for interventional medical devices.
EU Pharmaceutical Legislation Reform: Impact on Generics & Biosimilars 2026-27
The upcoming EU Pharmaceutical Legislation Reform will significantly influence the generics and biosimilars market, affecting drug availability and competition.
NOVI Health's Hybrid Care Model Bridges GLP-1 Drug Efficacy Gap Between Clinical Trials and Real-World Outcomes
NOVI Health introduces hybrid care approach to improve real-world GLP-1 obesity drug outcomes that typically underperform compared to clinical trials.